Ignite Creation Date:
2024-05-06 @ 3:02 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04500379
Status:
UNKNOWN
Last Update Posted:
2022-09-23
First Post:
2020-08-02
Brief Title:
Reliability and Validity of FIBSER STAR-P HEA Scale The Reliability and Validity of Chinese Version of FIBSER STAR-P HEA Scale in Depression Assessment
Sponsor:
Shanghai Mental Health Center
Organization:
Shanghai Mental Health Center
Study Overview
Official Title:
The Reliability and Validity of Chinese Version of FIBSER STAR-P HEA Scale in Depression
Status:
UNKNOWN
Status Verified Date:
2021-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
According to the survey of the World Health Organization the number of patients with depression in the world has reached 350 million has becoming the primary cause of disability and the main disease burden worldwide In order to better dealing with adverse reactions improving the doctor-patient relationship and optimizing the treatment cost FIBSER STAR-P and HEA Health Economics Follow-up Evaluation Scale are selected as simple and quick evaluation scales to evaluate the influence doctor-patient relationship and social and economic benefits after drug treatment in clinical treatment At present the reliability and validity of FIBSER STAR-P and HEA scales will be verified the reliability and validity of the above three scales in depressive disorder aiming at enriching the treatment of depressive patients based on assessment thus improving the compliance of medication for depressive disorder improving the doctor-patient relationship and reducing the total burden of social diseases
Detailed Description:
In this study the reliability and validity of FIBSER Scale Doctor-patient Relationship Scale-Patient Edition STAR-P and HEA in Chinese population will be verified to increase the diversity and selectivity of domestic assessment tools
This study includes two steps
1 baseline demographic data HAM-D HAM-A YMRS drug side effects scaleFIBSER TESS doctor-patient relationship scale STAR-P PDRQ-15Health economics follow-up evaluation scale SDS and HEA were evaluated
2 follow-up 4 weeks HAM-D HAM-A YMRS FIBSER STAR-P and HEA scale in order to verify the reliability of retest
This study includes two steps
1 baseline demographic data HAM-D HAM-A YMRS drug side effects scaleFIBSER TESS doctor-patient relationship scale STAR-P PDRQ-15Health economics follow-up evaluation scale SDS and HEA were evaluated
2 follow-up 4 weeks HAM-D HAM-A YMRS FIBSER STAR-P and HEA scale in order to verify the reliability of retest
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None